Frontline plc (NYSE: FRO) reported Q2 2025 profit of $77.5 million, down 59% from last year but up from Q1. Revenue was $480.1 million, beating estimates.
Johnson & Johnson ended a Phase 2a study of nipocalimab in rheumatoid arthritis after no added benefit was seen, but remains confident in its market potential.
Trump administration converts CHIPS Act grants into $5.7B equity stake in Intel, preventing spinoff of unprofitable foundry business and gaining leverage.